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Background

Phytonadione
• One proposed hemostatic strategy includes the
prophylactic use of phytonadione (Vitamin K), a fatsoluble vitamin which catalyzes the hepatic synthesis
of blood-clotting factors II, VII, IX, and X.
• Phytonadione is available in several formulations (PO,
IV, IM, SQ) and is commonly utilized as a safe and
effective method for the reversal of warfarin therapy.
• Based on the proposed mechanism of hepatic
dysfunction and pathophysiology of patients
undergoing mitral valve intervention, a local surgeon
implemented this theory into practice in effort to
advance patient care and outcomes.
• Supporting evidence regarding utilization of
phytonadione as surgical prophylaxis prior to mitral
valve intervention is currently limited.

Objectives
Primary
• Compare the rate of post-operative major bleeding
events in patients who received phytonadione
administration prior to surgical valve intervention
Secondary
• Compare the rates of antithrombotic utilization,
hemostatic agents and blood product utilization,
length of stay, and time to therapeutic INR
• Compare rates of mortality, re-admission, or reintervention within 30 days of hospital discharge

Methodology
• Single-center, single-surgeon retrospective chart
review study at a large tertiary medical center
• Inclusion criteria
• ≥18 years of age
• Underwent mitral valve replacement (MVR)
between January 2018 and June 2021
• Exclusion criteria
• Received phytonadione for warfarin reversal
• Emergent procedures
• IV phytonadione administered
• Severe renal impairment
• Potentially vulnerable populations
• Statistical analysis completed using t-test or Wilcoxon
rank sum test for continuous variables and chi-square
or Fisher exact test for categorical variables

Patient Baseline Characteristics

Anticoagulation & Antiplatelets

Characteristics on admission

Phytonadione

No
Phytonadione

Age, mean±SD
Female
Previous valve intervention
INR, median (IQR)
Hematocrit (%), median (IQR)
Hemoglobin (g/L), median (IQR)
CrCl, mean±SD
Co-morbidities
Atrial fibrillation
Chronic heart failure
Chronic kidney disease
Coronary artery disease
Diabetes mellitus
History of endocarditis
History of Stroke
History of PE/DVT
Hypertension

68.5±10.7
6 (75.0%)
2 (25.0%)
1.1 (1.0-1.2)
38.0±8.4
11.8±2.7
60.2±34.6

66.3±12.6
12 (66.7%)
3 (16.7%)
1.0 (1.0-1.0)
41.6±4.2
13.5±1.6
70.3±29.6

2 (25.0%)
3 (37.5%)
2 (25.0%)
3 (37.5%)
5 (62.5%)
1 (12.5%)
1 (12.5%)
0 (0.0%)
5 (62.5%)

7 (38.9%)
4 (22.2%)
2 (11.1%)
3 (16.7%)
4 (22.2%)
2 (11.1%)
2 (11.1%)
1 (5.6%)
15 (83.3%)

Medications

Phytonadione

No
Phytonadione

0 ( 0.0%)
2 (25.0%)
0 ( 0.0%)
6 (75.0%)

2 (11.1%)
5 (27.8%)
2 (11.1%)
9 (50.0%)

3 (37.5%)
2 (25.0%)
3 (37.5%)

7 (38.9%)
1 ( 5.6%)
10 (55.6%)

2 (25.0%)
3 (37.5%)
0 ( 0.0%)
3 (37.5%)

5 (27.8%)
6 (33.3%)
3 (16.7%)
4 (22.2%)

6 (75.0%)
1 (12.5%)
1 (12.5%)

16 (88.9%)
3 (16.7%)
1 ( 5.6%)

Anticoagulation prior to admit
Warfarin
Apixaban
Rivaroxaban
None
Antiplatelet prior to admit
Aspirin
Clopidogrel
None
Discharge anticoagulation
Warfarin
Apixaban
Rivaroxaban
None
Discharge antiplatelets
Aspirin
Clopidogrel
None

Table 1. Baseline characteristics; IQR = interquartile range

Table 2. Anticoagulants and antiplatelets received before and after surgery

Surgical and Phytonadione Characteristics
Operational Information
Elective surgery
Bio-prosthetic valve
Re-intervention

Phytonadione (n=8)
6 (75.0%)
7 (87.5%)
2 (25.0%)

No Phytonadione (n=18)
15 (83.3%)
15 (83.3%)
3 (16.7%)

p-value
0.628
>0.999
0.628

Table 3. Mitral valve surgical characteristics reported as number of patients (%)

Phytonadione Doses Administered

20
Doses Administered

Cardiac Procedures & Hepatic Dysfunction
• Per ACC/AHA guidelines, surgical or percutaneous
interventions are recommended for severe
degenerative mitral valve disease, which are
associated with various degree of body organ
dysfunction, likely due to systemic inflammatory
response and oxidative stress.
• In high-risk surgeries, 10% of patients experience
hepatic injury, increasing complications related to
degree of coagulopathy, including bleeding events,
thromboembolic events, and valve thrombosis.
• Blood transfusions secondary to bleeding events
during or following cardiac operations has been
shown to worsen short- and long-term outcomes for
patients.

Discussion

Results
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Post-op bleeding, no (%)

Phytonadione (n=8)

No Phytonadione (n=18)

p-value

1 (12.5%)

4 (22.2%)

>0.999

Table 4. Post operative bleeding rates in patients that receive phytonadione versus those who did not

Phytonadione (n=8)
No phytonadione (n=18)

Products Given During or Following Procedure
100.0%

100%

100.0%

80%

66.7%

60%

44.4%

40%
20%
0%

0.0%

5.6%

Recombinant factor VIIa

Anti-inhibitor coagulant complex

p>0.999

p=0.009

Blood products (FFP, pRBCs)
p=0.132

Figure 2a-c. Percentages of patients that received recombinant factor VIIa, anti-inhibitor coagulant complex and/or blood products during or following
procedure; FFP = fresh frozen plasma, pRBC = packed red blood cells

Secondary Outcomes
Re-admission within 30 days for bleeding
Re-intervention within 30 days
Mortality within 30 days
Therapeutic INR obtained during admission
LOS, median (IQR)
POLOS, median (IQR)

Primary Outcome
• Patients who had received phytonadione
supplementation (n=8), compared to those who did
not (n=18), were found to have less postoperative
bleeding events (12.5% vs. 22.2%, p>0.999)
Secondary Outcomes
• Phytonadione study group significantly received more
anti-inhibitor coagulant complex during admission
(100% vs. 44.4%, p=0.009) and had longer length of
stay (17 days vs. 9 days, p=0.02)
• Mortality, re-admission rates due to bleeding, reintervention rates, and time to therapeutic INR were
similar between both groups

Conclusion

Figure 1. Total doses (#) of oral phytonadione ordered and administered

Primary Outcome

Phytonadione Administered
• On average, oral phytonadione was supplemented
with a strength of 5 mg for 3.4 doses prior to MVR

Study Limitations
• Retrospective, non-randomized single-center study
• Small sample size
• Variations in phytonadione doses administered
• Inconsistencies in electronic medical record
documentation of bleeding outcomes
• Presence of hepatic disorders were not identified
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Patient Population
• 26 patients met inclusion and exclusions criteria
• The average study patient was a 68-year-old female
(69.2%) who underwent elective bio-prosthetic MVR
as their first valvular intervention

Phytonadione

No Phytonadione

p-value

1 (66.7%)
0 ( 0.0%)
1 (12.5%)
1 (50.0%)
17.0 (14.8-21.0)
12.0 (9.0-16.8)

4 (33.3%)
3 (16.7%)
0 ( 0.0%)
3 (40.0%)
9.0 (8.0-14.0)
8.0 (8.0-13.8)

0.683
0.529
0.308
>0.999
0.02
0.4

Table 5. Secondary outcomes; INR = international normalized ratio, LOS = length of stay, POLOS = post-op length of stay, IQR = interquartile range

• In patients undergoing mitral valve replacement,
phytonadione supplementation did not significantly
decrease the rate of postoperative bleeding events
and was associated with an increase in anti-inhibitor
coagulant complex utilization and longer
hospitalization length of stay.

Future Considerations
• Given study limitations, benefit of prophylactic
phytonadione cannot be completely ruled out.
• Considerations for future research include a larger,
prospective, multi-center, randomized study with
standardized phytonadione dosing and defined
criteria of patients who would be eligible for
supplementation.
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